Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Open Access
- 1 June 2025
- journal article
- review article
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 523-529
Abstract
Triple-negative breast cancer (TNBC) represents a particularly aggressive and heterogeneous subtype of breast cancer, associated with poor prognosis and limited treatment options. This review delves into the rising incidence of TNBC, particularly among younger women, and explores the significant demographic disparities that contribute to variations in incidence, treatment access and survival outcomes. We provide a discussion of TNBC’s molecular and genetic landscape, including key pathways revolving around TP53, BRCA1/2 mutations, and PI3K/AKT signaling, which have informed the development of targeted therapies. Recent practice-changing studies are highlighted, which have resulted in the integration of immune checkpoint inhibitors in both early-stage and metastatic settings, the application of PARP inhibitors for BRCA-mutated TNBC and the introduction of antibody-drug conjugates as valuable new therapeutic options. We also review the role of neoadjuvant chemotherapy, novel biomarkers such as tumor-infiltrating lymphocytes, and advancements in diagnostic tools, including machine learning-based imaging and spatial transcriptomics, which are all driving shifts towards personalized approaches. This review synthesizes emerging research and major changes in clinical practice to provide a concise overview of the recent innovations and upcoming trends in TNBC diagnosis and therapy.Keywords
This publication has 81 references indexed in Scilit:
- Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast CancerJAMA Oncology, 2024
- Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerJAMA, 2024
- Epigenetic Profiles of Triple-Negative Breast Cancers of African American and White FemalesJAMA Network Open, 2023
- Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019JAMA Network Open, 2023
- Combined diagnosis of multiparametric MRI-based deep learning models facilitates differentiating triple-negative breast cancer from fibroadenoma magnetic resonance BI-RADS 4 lesionsJournal of Cancer Research and Clinical Oncology, 2022
- Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancerBreast Cancer Research and Treatment, 2021
- Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast CancerJAMA Oncology, 2021
- Association of Insurance Status and Racial Disparities With the Detection of Early-Stage Breast CancerJAMA Oncology, 2020
- Breast Cancer TreatmentJAMA, 2019
- Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancerBreast Cancer Research and Treatment, 2016